Generating Innovation with Japan (GIJ) Series: BC 2021

Generating Innovation with Japan (GIJ):
BC 2021 - HealthTech

     Unique Opportunity for Start-ups to Meet Potential Japanese Partners

Major Japanese firms, in a whole variety of areas but especially in healthtech-related sectors, are increasingly looking to identify new innovation from Canadian start-ups in order to improve their business practices and to introduce new ideas and technology into the Japanese market and to their network of global clients.

For Canadian start-ups, the Japanese market (approx.. GDP: US$5 trillion; Pop.: 126 million) can be daunting but potentially hugely rewarding. In Japan, people over the age of 65 already account for 1 in 4 of the population and this is expected to reach 1 in 3 by 2036. As Japan deals with such a rapidly aging population, new healthtech innovations, from therapeutics to medical devices to care-giving tools, are urgently needed.

One of the best ways to enter this market is through partnering with Japanese firms. This on-line event will provide a unique opportunity for start-ups and major Japanese firms to connect and share information. Through reverse-pitch presentations, Japanese firms will explain about their technology and innovation needs and, during the one-on-one meeting programme, selected start-ups can explain about their technology solutions.

Through this programme, we aim to generate new innovation through partnerships between leading Japanese firms and innovative Canadian start-ups.

What is a Generating Innovation with Japan (GIJ) Reverse-pitch Event?

This event will provide a unique opportunity for start-ups and Japanese companies to connect and share information. Through reverse-pitch presentations, Japanese firms will explain about their innovation needs and, during the breakout sessions and B2B meeting programme, start-ups can present their technology solutions. Through this event, we aim to generate new innovation through partnerships between leading Japanese firms and innovative Canadian start-ups.

Organizers	Japan External Trade Organization (JETRO) BC Government Global Affairs Canada
Supporting Organizers	adMare Bioinnovations BC Cancer Creative Destruction Labs Digital Supercluster NRC-IRAP
Date/Time	Japanese Company Reverse-pitch Canada: Tuesday, March 9, 2021 (4:00-5:30 pm PST / 7:00-8:30 pm EST) Japan: Wednesday, March 10, 2021 (9:00-10:30 am JST) Pre-arranged B2B Meetings: Canada: March 10, 11 and/or 12 (possibly March 15 & 16 if needed)
Venue	Online (Zoom Platform)
Agenda	1. Welcome / Opening Remarks 2. Overview of JETRO Services and Support 3. Japanese Company Reverse-pitch Presentations Astellas Pharma Inc. Daiichi Sankyo Hike Ventures Kissei America, Inc. Maruho Co., Ltd. NTT DATA Taiho Pharma Takeda Pharmaceutical Company Limited ※See Japanese Company Profiles below for details.
Japanese Company Profiles	Astellas Pharma Inc. Astellas Pharma Inc., headquartered in Tokyo, Japan, is a top 20 global pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. With a strong track record of proven innovation and success, the organization pursues global leadership in the primary strategic areas of urology transplantation and oncology. Our broader business focuses include oncology, immunology, ophthalmology, and others with high unmet medical needs. We seek out partners who offer access to valuable resources, products, expertise, and relationships that result in products which address unmet medical needs or provide significant improvements over existing therapies. We also seek out partnerships based on game-changing technologies that enable us to evolve ways of producing therapeutics such as peptides, nucleotides, proteins, genes, cells, and other new modality-related therapeutics. We have successfully partnered with key stakeholders at all levels, including entrepreneurial biotechnology and pharmaceutical companies, and government and academic laboratories. Our partnerships encompass global markets or select geographies in major or emerging markets. We have leveraged creative and flexible partnerships, as well as strategic acquisitions to drive us toward our goal of changing tomorrow for patients and our local communities. https://www.astellas.com/en/partnering Daiichi Sankyo Daiichi Sankyo is a global pharmaceutical company. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. We attach significant importance to working with academic institutions and biotech companies to discover new therapeutics in the place where hypotheses are brought and tested in order to expand possibilities for scientific innovation breakthrough. We build sustainable relationships with partner institutions and companies through open and fair alliance management and trust based on mutual respect as the foundation for effective collaborations. Our goal is to jointly create new value for patients by maximizing each other’s expertise and strengths. Daiichi Sankyo website: https://www.daiichisankyo.com/ Our Areas of Interest　⇐Click here Hike Ventures Hike Ventures is a seed-stage venture capital based in San Francisco, Toronto, and Tokyo. We are looking for founders who are solving well-defined problems by leveraging AI. We are industry agnostic. In the past, we have invested in startups in healthcare, legal, supply chain, and mobility spaces. We work with our portfolio founders to hit the next milestone. We also leverage our network with Japanese companies to help startups at any stage to go to the Japan market. https://hikevc.com/ Presentation Kissei America, Inc. Kissei is one of the public middle size Japanese pharmaceutical companies. The annual sales is about 580 MM USD. We are the R&D oriented company and invest in the R&D activity more than 15% of net sales every year. Our focus areas are urology, renal diseases including dialysis, and any other indications having the unmet medical needs including rare diseases. We are also interested in neurology, hematology, GI, and women's health. We have full functions including discovery, non-clinical, CMC, clinical, pharmacovigilance, sales & marketing and so on in Japan. As a Japanese pharmaceutical company, we have a lot of licensing activities and experiences for in-licensing for Asian territory and out-licensing of our original new pharmaceutical agents. We also have many experiences of R&D collaboration with biotech and academia. We would like to explore the business collaboration opportunities for innovative assets and technology. https://www.kissei.co.jp/e_contents/ Presentation Maruho Co.,Ltd. Maruho has contributed to people's health and better living for over 100 years since its founding in 1915. Currently, as a pharmaceutical company specializing in dermatology, we are developing business activities aimed at improving the QOL (Quality of Life) of patients. In 2011, we launched our Long-Term Vision with the theme "Excellence in Dermatology", and we have strived to make further contributions to patients suffering from skin diseases. This new vision is designed to integrate dermatology-related knowledge and expertise from around the world, and to innovate along each step of the dermatological care cycle (prevention, diagnosis, treatment, and aftercare). As a result of this commitment and focus, Maruho has the leading sales in the dermatology market in Japan and is No.1 in Japanese dermatology field. Our focus area is the field of dermatology, however since we think there are possibilities even something new for us can be applied for skin diseases and vice versa, we are seeking inspiration and ideas as well as new agents and technologies. https://www.maruho.co.jp/english/index.html NTT DATA NTT DATA Corporation, is a top 10 global IT services provider with 130,000+ employees in more than 50 countries, headquartered in Tokyo. We excel in blending IT and business expertise with decades of industry know-how. We offer one of the industry’s most comprehensive services portfolios, designed to modernise business and technology to deliver the outcomes that matter most to our clients. Innovation that makes a difference is at the heart of what we do, especially in our Healthcare practice. We partner with you to simplify the complexities of business and technology, delivering the insights, solutions and outcomes that matter most. Our global healthcare team, currently has 3 pillars for innovation. 1. Disease Prevention. 2. Patient Outcome Optimization. 3. Remote Care. We welcome start-ups who can provide evidence based results through existing case studies to reach out to our Healthcare team at this Jetro hosted event. We will have leaders from our Japanese and Canadian healthcare teams at the event. https://ca.nttdata.com/en/ Presentation Taiho Pharma Taiho Pharma Canada, Inc. works urgently to discover and develop innovative cancer treatments. As cancer evolves, we evolve with it―bringing novel technology to cornerstone chemotherapies, while at the same time optimizing new targeted agents. Advanced technology, dedicated investigators, and incomparable facilities―these vast resources empower us to redefine the way the world treats cancer. Furthermore, Taiho Pharma Canada exists to extend our important global research projects into Canada and to similarly look for Canadian innovation that can be included in our global endeavor to improve the lives of cancer patients. We look to create partnerships that can develop specific targeted therapies that will make a difference to the future of healthcare. It’s our work; it’s our passion; it’s our legacy. https://www.taihopharma.ca/en/ Presentation Takeda Pharmaceutical Company Limited Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in our distinguished history in Japan since 1781. Neuroscience is a core therapeutic area for Takeda. Our drug discovery approach is to focus on the patient to understand their needs and to pursue cutting edge science to create medicines that can transform their quality of life. Our focused diseases are age-related and hereditary neurological diseases and neuromuscular disorders. From the initial idea to the launch of the medicine we are committed to working in partnership with external experts who share our vision and possess the knowledge and scientific capabilities to make truly transformational medicines for the patients we serve. Takeda Global Website https://www.takeda.com/ Takeda Research Wishlist  (see English at bottom of document)　 https://www.takeda.com/4ac944/siteassets/jp/home/what-we-do/research--development/open-innovation/wishlist_takeda_oct2020.pdf Presentation
Registration	This event is free of charge but pre-registration is mandatory.
Registration Deadline	Closed
Contact	JETRO Toronto Email: inquiry@jetro.go.jp